AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

AbbVie has claimed FDA approval for Emblaveo, a new antibiotic product to treat complicated intra-abdominal infections (cIAI) ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

It's the first and only such therapy approved to fight antimicrobial resistance, or AMR, in bacterial infections.

AbbVie (ABBV) said it has received FDA approval for the combination antibiotic treatment Emblaveo, which was co-developed ...

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first ...